Literature DB >> 24091486

Postmortem brain: an underutilized substrate for studying severe mental illness.

Robert E McCullumsmith1, John H Hammond, Dan Shan, James H Meador-Woodruff.   

Abstract

We propose that postmortem tissue is an underutilized substrate that may be used to translate genetic and/or preclinical studies, particularly for neuropsychiatric illnesses with complex etiologies. Postmortem brain tissues from subjects with schizophrenia have been extensively studied, and thus serve as a useful vehicle for illustrating the challenges associated with this biological substrate. Schizophrenia is likely caused by a combination of genetic risk and environmental factors that combine to create a disease phenotype that is typically not apparent until late adolescence. The complexity of this illness creates challenges for hypothesis testing aimed at understanding the pathophysiology of the illness, as postmortem brain tissues collected from individuals with schizophrenia reflect neuroplastic changes from a lifetime of severe mental illness, as well as treatment with antipsychotic medications. While there are significant challenges with studying postmortem brain, such as the postmortem interval, it confers a translational element that is difficult to recapitulate in animal models. On the other hand, data derived from animal models typically provide specific mechanistic and behavioral measures that cannot be generated using human subjects. Convergence of these two approaches has led to important insights for understanding molecular deficits and their causes in this illness. In this review, we discuss the problem of schizophrenia, review the common challenges related to postmortem studies, discuss the application of biochemical approaches to this substrate, and present examples of postmortem schizophrenia studies that illustrate the role of the postmortem approach for generating important new leads for understanding the pathophysiology of severe mental illness.

Entities:  

Mesh:

Year:  2013        PMID: 24091486      PMCID: PMC3857666          DOI: 10.1038/npp.2013.239

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  270 in total

1.  Detection and characterization of protein nitrosothiols.

Authors:  Samie R Jaffrey
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

2.  Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins.

Authors:  S L Eastwood; P J Harrison
Journal:  Brain Res Bull       Date:  2001-07-15       Impact factor: 4.077

3.  [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia.

Authors:  P W Burnet; S L Eastwood; P J Harrison
Journal:  Neurochem Int       Date:  1997-06       Impact factor: 3.921

4.  The interaction between Stargazin and PSD-95 regulates AMPA receptor surface trafficking.

Authors:  Cecile Bats; Laurent Groc; Daniel Choquet
Journal:  Neuron       Date:  2007-03-01       Impact factor: 17.173

5.  Protein S-nitrosylation: a physiological signal for neuronal nitric oxide.

Authors:  S R Jaffrey; H Erdjument-Bromage; C D Ferris; P Tempst; S H Snyder
Journal:  Nat Cell Biol       Date:  2001-02       Impact factor: 28.824

6.  Clustering and synaptic targeting of PICK1 requires direct interaction between the PDZ domain and lipid membranes.

Authors:  Lifeng Pan; Hao Wu; Chong Shen; Yawei Shi; Wenying Jin; Jun Xia; Mingjie Zhang
Journal:  EMBO J       Date:  2007-10-04       Impact factor: 11.598

7.  Preliminary evidence of ubiquitin proteasome system dysregulation in schizophrenia and bipolar disorder: convergent pathway analysis findings from two independent samples.

Authors:  Chad A Bousman; Gursharan Chana; Stephen J Glatt; Sharon D Chandler; Ginger R Lucero; Erick Tatro; Todd May; James B Lohr; William S Kremen; Ming T Tsuang; Ian P Everall
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

8.  Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse.

Authors:  Mari S Golub; Stacey L Germann; K C Kent Lloyd
Journal:  Behav Brain Res       Date:  2004-08-12       Impact factor: 3.332

9.  DISC1 Pathway in Brain Development: Exploring Therapeutic Targets for Major Psychiatric Disorders.

Authors:  Atsushi Kamiya; Thomas W Sedlak; Mikhail V Pletnikov
Journal:  Front Psychiatry       Date:  2012-03-22       Impact factor: 4.157

10.  Removal of AMPA receptors (AMPARs) from synapses is preceded by transient endocytosis of extrasynaptic AMPARs.

Authors:  Michael C Ashby; Sarah A De La Rue; G Scott Ralph; James Uney; Graham L Collingridge; Jeremy M Henley
Journal:  J Neurosci       Date:  2004-06-02       Impact factor: 6.167

View more
  41 in total

1.  Human and rodent temporal lobe epilepsy is characterized by changes in O-GlcNAc homeostasis that can be reversed to dampen epileptiform activity.

Authors:  Richard G Sánchez; R Ryley Parrish; Megan Rich; William M Webb; Roxanne M Lockhart; Kazuhito Nakao; Lara Ianov; Susan C Buckingham; Devin R Broadwater; Alistair Jenkins; Nihal C de Lanerolle; Mark Cunningham; Tore Eid; Kristen Riley; Farah D Lubin
Journal:  Neurobiol Dis       Date:  2019-01-06       Impact factor: 5.996

2.  IL-38 inhibits microglial inflammatory mediators and is decreased in amygdala of children with autism spectrum disorder.

Authors:  Irene Tsilioni; Harry Pantazopoulos; Pio Conti; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

3.  Altered fucosyltransferase expression in the superior temporal gyrus of elderly patients with schizophrenia.

Authors:  Toni M Mueller; Stefani D Yates; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2016-10-20       Impact factor: 4.939

4.  Expression quantitative trait loci (eQTLs) in microRNA genes are enriched for schizophrenia and bipolar disorder association signals.

Authors:  V S Williamson; M Mamdani; G O McMichael; A H Kim; D Lee; S Bacanu; V I Vladimirov
Journal:  Psychol Med       Date:  2015-03-30       Impact factor: 7.723

5.  Altered serine/threonine kinase activity in schizophrenia.

Authors:  Jennifer L McGuire; John H Hammond; Stefani D Yates; Dongquan Chen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Brain Res       Date:  2014-04-26       Impact factor: 3.252

Review 6.  Extracellular matrix proteomics in schizophrenia and Alzheimer's disease.

Authors:  Manveen K Sethi; Joseph Zaia
Journal:  Anal Bioanal Chem       Date:  2016-09-06       Impact factor: 4.142

Review 7.  Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments.

Authors:  Takeshi Sakurai; Nao J Gamo; Takatoshi Hikida; Sun-Hong Kim; Toshiya Murai; Toshifumi Tomoda; Akira Sawa
Journal:  Prog Neurobiol       Date:  2015-09-25       Impact factor: 11.685

8.  IL-37 is increased in brains of children with autism spectrum disorder and inhibits human microglia stimulated by neurotensin.

Authors:  Irene Tsilioni; Arti B Patel; Harry Pantazopoulos; Sabina Berretta; Pio Conti; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-07       Impact factor: 11.205

Review 9.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

10.  The NSW brain tissue resource centre: Banking for alcohol and major neuropsychiatric disorders research.

Authors:  G T Sutherland; D Sheedy; J Stevens; T McCrossin; C C Smith; M van Roijen; J J Kril
Journal:  Alcohol       Date:  2016-03-14       Impact factor: 2.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.